OCC Quarterly Report | Quarter ended 31 December 2024

Orthocell has today released its Quarterly Report for the period ended 31 December 2024. This report rounds out a record period of growth for the Company and a rewarding end to the calendar year for everyone invested in Orthocell’s clinical and commercial success. Key highlights for the Quarter include: 

• Third consecutive quarter of record revenue, reporting $2.21 million in the December ‘24 Quarter
• Revenue up 9% on the previous record of $2.03 million achieved in the September ‘24 Quarter
• Revenue is also up 46% on the previous corresponding December ‘23 Quarter of $1.51 million

Orthocell CEO and MD, Paul Anderson, said:“We are delighted with the continued growth in demand and record quarterly revenue for our market-leading products Striate+ and Remplir. The majority of revenue growth is in existing markets, demonstrating increasing market traction, driven by the consistent and predictable outcomes surgeons can achieve using our products. We are excited by the potential for exponential growth and believe we are on track to become a key player in the US$4.5 billion global market we are targeting. The near-term US FDA approval which we expect in March / April 2025 will be a very significant catalyst of value for the Company, opening up the substantial US$1.6 billion US nerve repair market.” Click to read the ASX release.